# Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations

> **NCT00891579** · PHASE2 · COMPLETED · sponsor: **Chinese Society of Lung Cancer** · enrollment: 161 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Pemetrexed (Alimta)
- **DRUG:** Gefitinib (IRESSA)

## Key facts

- **NCT ID:** NCT00891579
- **Lead sponsor:** Chinese Society of Lung Cancer
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2012-09
- **Final completion:** 2012-11
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2012-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00891579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00891579, "Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00891579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*